Waddell & Reed Financial’s NovoCure NVCR Stock Holding History

Waddell & Reed Financial’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-180,000	Closed	-$10.7M	–	476
2020 Q2	$10.7M	Sell	180,000 -119,737	-40%	-$7.87M	0.03%	376
2020 Q1	$20.2M	Buy	299,737 +1,680	+0.6%	+$133K	0.07%	282
2019 Q4	$25.1M	Sell	298,057 -9,997	-3%	-$807K	0.06%	309
2019 Q3	$23M	Sell	308,054 -81,757	-21%	-$6.54M	0.06%	310
2019 Q2	$24.6M	Sell	389,811 -134,213	-26%	-$6.8M	0.06%	309
2019 Q1	$25.2M	Sell	524,024 -687,935	-57%	-$33.1M	0.06%	312
2018 Q4	$40.6M	Buy	1,211,959 +177,008	+17%	+$6.47M	0.11%	224
2018 Q3	$54.2M	Sell	1,034,951 -235,838	-19%	-$9.39M	0.12%	199
2018 Q2	$39.8M	Sell	1,270,789 -35,300	-3%	-$982K	0.09%	246
2018 Q1	$28.5M	Buy	1,306,089 +423,149	+48%	+$9.1M	0.06%	285
2017 Q4	$17.8M	Buy	+882,940	New	+$17M	0.04%	352

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

DCP

Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Waddell & Reed Financial's NVCR Position: Q3 2020 in Review

Waddell & Reed Financial sold out of NovoCure (NVCR) in Q3 2020, closing a stake of 180,000 shares — an estimated $10.7M sold.

Waddell & Reed Financial first reported a position in NVCR in Q4 2017 and held it in 11 quarters. The position peaked at $54.2M in Q3 2018. 282 funds tracked by Wall St. Rank hold NVCR as of Q3 2020.

Waddell & Reed Financial reported no remaining NovoCure position as of Q3 2020 after selling out during the quarter.
Waddell & Reed Financial sold 180,000 NovoCure shares in Q3 2020, an estimated $10.7M.
Waddell & Reed Financial first reported a position in NovoCure in Q4 2017 and held it in 11 quarters.
Waddell & Reed Financial's NovoCure position peaked at $54.2M in Q3 2018.
282 funds tracked by Wall St. Rank held NovoCure as of Q3 2020.

Based on Waddell & Reed Financial's 13F filing for Q3 2020, filed 13 Nov 2020.